Nebulized albuterol in acute bronchiolitis

Area of Science:

• Pediatrics
• Pulmonology
• Pharmacology

Background:

• Bronchiolitis is a common viral respiratory infection in infants.
• Wheezing and accessory muscle use are key indicators of respiratory distress in bronchiolitis.
• Current treatment options for bronchiolitis are primarily supportive.

Purpose of the Study:

• To evaluate the efficacy and safety of nebulized albuterol in infants with bronchiolitis.
• To assess the impact of albuterol on respiratory parameters such as accessory muscle score, oxygen saturation, and respiratory rate.

Main Methods:

• A double-blind, placebo-controlled trial involving 40 infants (6 weeks to 24 months) with a first episode of bronchiolitis.
• Participants received either nebulized albuterol (0.15 mg/kg/dose) or placebo (saline solution) for two administrations, 1 hour apart.
• Viral identification was performed on nasal specimens.

Main Results:

• Albuterol significantly improved accessory muscle score and oxygen saturation after one dose.
• After two doses, albuterol showed significant improvements in accessory muscle score, respiratory rate, and oxygen saturation compared to placebo.
• Treatment response was consistent across different age groups within the study population.
• No significant side effects were observed, with a slight increase in heart rate in the albuterol group.

Conclusions:

• Nebulized albuterol is a safe and effective treatment for infants diagnosed with bronchiolitis.
• The study supports the use of albuterol for managing respiratory symptoms in this pediatric population.
• Respiratory syncytial virus (RSV) was the most common viral pathogen identified.